Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

TONIX Closes PK Study On New Formulation Of TNX-102 For Fibromyalgia

Tonix Pharmaceuticals Holding Corp (TNXP.OB), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system or "CNS", said that it completed a pharmacokinetic or PK study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome or "FM".

The company noted that the study results support further development of TNX-102 as a product that can potentially deliver benefits similar to those observed in FM patients treated with very low dose cyclobenzaprine in the Company's dose-escalating Phase 2a study.

TONIX said that it is developing new formulations of cyclobenzaprine that are designed for bedtime use. The Company is investigating different technologies to improve the absorption of cyclobenzaprine. The technology applied in this study involves a mixture of cyclobenzaprine and lipids that the Company obtained from Lipocine, Inc. and is designated TNX-102 2.4 mg promicellar gelatin capsules, or gelcaps.

TONIX said that it is on track to initiate a pivotal efficacy study with the final formulation of TNX-102 in the first quarter of 2013.

Register
To receive FREE breaking news email alerts for and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After ending the previous session modestly lower, stocks have shown a strong move back to the upside during trading on Tuesday. With the upward move on the day, the S&P 500 has reached a new record intraday high. A majority of Americans believe Israel is justified in taking military action against Gaza, according to the results of a new CNN/ORC International survey, although opinions about the amount of military force the Israelis have used are more divided. After reporting a sharp increase in existing home sales in the previous month, the National Association of Realtors released a report on Tuesday showing that existing home sales once again rose by more than expected in the month of June.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.